The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...
HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February ...
Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin ...
Read more about evidence based treatments that can help you reduce your alcohol use, particularly if you are finding it ...
ScienceAlert on MSN6d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
A recent clinical trial found that combining the oral medication baricitinib with narrowband UV-B light therapy significantly ...
Maharashtra’s health minister, Prakash Abitkar, during a visit to Pune a few days ago, says that the recent GBS outbreak in the city was most likely due to contaminated water sources.
To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1‐800-FDA-1088 or .
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback